Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Unit-I of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The US FDA inspected Unit-I, an API manufacturing facility of Aurobindo Pharma's wholly owned subsidiary Apitoria Pharma, located in Sangareddy, Telangana, from August 21 to August 29, 2025. At the end of the inspection, the US FDA issued a Form 483 with 5 observations, all described as procedural in nature with no data integrity issues flagged. The company has stated it will respond to the US FDA within the required timelines and confirmed there is no material impact on its financials or operations from this inspection.
The outcome is broadly reassuring for investors — a Form 483 with only minor procedural observations and no data integrity concerns is generally viewed as a routine regulatory finding that should not disrupt production or US supplies. No immediate negative effect on financials or operations is expected, though investors may watch for the company's response and any follow-up classification from the US FDA.